Progress forecasts FY2026 EPS of $6.09-$6.21 while targeting net leverage of ~2.8x (NASDAQ:PRGS)July 1, 2026
Elite Pharmaceuticals outlines ropinirole launch next month and targets 5% to 10% of its $12M market (OTCMKTS:ELTP)June 30, 2026
Share Facebook Twitter LinkedIn Pinterest Email Wall Street rises on tech rebound and easing U.S.-Iran tensions
Progress forecasts FY2026 EPS of $6.09-$6.21 while targeting net leverage of ~2.8x (NASDAQ:PRGS)July 1, 2026
Elite Pharmaceuticals outlines ropinirole launch next month and targets 5% to 10% of its $12M market (OTCMKTS:ELTP)June 30, 2026
